MASIMO Business Summary

Masimo Corporation (MASI) is a global medical technology leader that generates revenue primarily through the sale of noninvasive patient monitoring systems, high-margin disposable sensors, and hospital automation solutions. The company operates through two primary segments: Healthcare, which accounts for the vast majority of its $1.52 billion in 2025 revenue, and a Consumer Audio segment that was recently divested to refocus on core clinical technologies. Masimo’s business model relies on a "razor-and-blade" strategy, where the placement of proprietary pulse oximetry and CO-Oximetry bedside monitors drives long-term recurring revenue from specialized sensors. In the competitive landscape, Masimo maintains a premium market position against major incumbents like Medtronic, Philips, and GE Healthcare by leveraging its superior Signal Extraction Technology (SET), which is clinically recognized for its accuracy during patient motion and low perfusion. Founded in 1989 by Joe Kiani, Masimo underwent a significant leadership transformation in early 2025 following a high-profile proxy battle. The current executive team is led by CEO Katie Szyman, who joined in February 2025 after serving as Worldwide President of Advanced Patient Monitoring at Edwards Lifesciences and holding senior roles at Medtronic. She is supported by CFO Micah Young and Ammar Al-Ali, the Chief of Engineering, Innovation & Design, who is a prolific inventor with over 1,000 patents and a pioneer of the company’s core SET technology. The board is chaired by Michelle Brennan, a former Johnson & Johnson executive, and includes Vice Chairman Quentin Koffey, Managing Partner of Politan Capital Management, reflecting a strategic shift toward operational efficiency and shareholder value creation.